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Impact of Extended Interval INR Testing During the
COVID-19 Pandemic
Jordan L Holder, PharmD; Maryam Noureldin, PharmD, BCPS,BCACP; Priya Verma, PharmD
Parkview Regional Medical Center
Fort Wayne, Indiana

RESULTS

BACKGROUND
• Warfarin is an oral anticoagulant that requires regular monitoring of the
international normalized ratio (INR).

• Time in therapeutic range (TTR) represents the percentage of time in which the INR
remains within target range across time.
• TTR in a controlled environment is usually 55-65%, with 65% or greater being ideal
for efficacy and safety standards.3,4,5
• The COVID 19 global pandemic prompted recommendations from the Centers of
Disease Control and Prevention (CDC) for the general public to practice social
distancing to limit exposure of SARS COV-2. This is especially for those at higher
risk for COVID-related complications.5,6
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• Warfarin is used in the treatment and prevention of venous thrombosis, pulmonary
embolism and thromboembolic complications of atrial fibrillation and valve
replacements, among other disease states.1
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To determine if extended INR interval monitoring during the COVID-19 pandemic
would significantly impact TTR or be associated with emergency department (ED)
visits and hospitalizations with bleeding or clotting events.

Figure 4

Greater than or equal to 65%

Less than 65%

METHODS

12 Week Extension
TTR >65%, 4
consecutive INRs in
range, on warfarin for
at least 3 months

Time in Therapeutic Range

95

Atrial fibrillation
PE
DVT
Mechanical Heart Valve

202
37
32
30

Other thrombus
Genetic Condition

7
6

Other

16

Goal INR
Range
1.5-2.0

# of Patients

1.5-2.5

2

1.8-2.5

1

2.0-3.0

314

2.5-3.5

10

3

Figure 7

90.33

P value= 0.4723

90
84.53

85
80

75

65

Baseline TTR

• There was a slight reduction in TTR from baseline extension. However, this was
not a statistically significant decrease from baseline.
• Majority of the patients continued to have a TTR >65% indicating continued
efficacy of warfarin management There were seven bleeding events and two
clotting events attributable to six unique patients. Bleeding events were not
correlated with INRs >6.0.
• The majority of patients at the clinic are considered high-risk for COVID-related
complications, and this study showed risk of adverse events is low with
extended INR interval monitoring.
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DISCUSSION & CONCLUSIONS

OBJECTIVES

• This IRB-exempt study was a retrospective chart review of anticoagulation visits
conducted from March 1st, 2020 to October 1st 2020.
• Patients had to meet prespecified criteria for extension. (Figure 2)
• All encounters reviewed were documented by the pharmacist and included a
prespecified phrase to notify the team of the extended interval monitoring.
• Outcomes included: TTR at baseline in comparison to TTR at end of extension,
bleeding or clotting events that require hospitalization or ED visit(s), and any
minor bleeding events that required medical attention.
• Inclusion criteria: extended appropriately within the study time period and have at
least one visit after initial extension.
• Exclusion criteria: Patients with inappropriate extension or no follow-up visit in the
study timeframe after initial extension.
• A student t-test and descriptive statistics were used for data analysis.
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• Due to the nature of indications for warfarin therapy, most warfarin patients are
high-risk for COVID-related complications. Parkview Health took a multi-pronged
approach to limit exposure. Strategies included: switching patients to alternative
anticoagulation therapy, utilizing a patient self-testing (PST) program, using a drivethru testing service, and instituting an extended interval INR monitoring protocol.
(Figure 1)
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• A total of 330 patients met inclusion criteria.
• 128 patients were female, 202 were male
• Majority of patients had a diagnosis of atrial fibrillation, a goal INR range
of 2.0-3.0, and were aged 61-90. (Figure 3, 6, and 7)
• During the study time period there were 4/2882 (0.14%) INRs >6 over seven
months
• There was one bleeding event requiring an office visit, five bleeding events
requiring either an ED visit or hospitalization, and two hospital visits for
clotting events. Overall, 6/330 (1.82%) of patients experienced at least one
bleeding event
• One bleeding event requiring hospitalization had a subtherapeutic INR at
the visit prior to the event, all other INRs were therapeutic at the visit
prior to event
• 16/330 (<5%) of patients were not extended after initial extension.

TTR after study completion
Figure 5
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